# A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)

> **NCT00856635** · PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 44 (actual)

## Conditions studied

- Optic Neuritis

## Interventions

- **DRUG:** Glatiramer Acetate
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00856635
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2010-12
- **Final completion:** 2011-02
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2018-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00856635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00856635, "A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00856635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*